4.33
price up icon0.46%   0.02
after-market 시간 외 거래: 4.33
loading
전일 마감가:
$4.31
열려 있는:
$4.39
하루 거래량:
127.76K
Relative Volume:
0.64
시가총액:
$196.13M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-8.8367
EPS:
-0.49
순현금흐름:
$-27.23M
1주 성능:
-0.69%
1개월 성능:
-1.81%
6개월 성능:
-30.05%
1년 성능:
-62.64%
1일 변동 폭
Value
$4.30
$4.50
1주일 범위
Value
$4.20
$4.50
52주 변동 폭
Value
$3.55
$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
명칭
Y Mabs Therapeutics Inc
Name
전화
646-885-8505
Name
주소
202 CARNEGIE CENTER, PRINCETON, NY
Name
직원
107
Name
트위터
Name
다음 수익 날짜
2025-03-04
Name
최신 SEC 제출 서류
Name
YMAB's Discussions on Twitter

YMAB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.33 197.49M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-22 다운그레이드 BofA Securities Neutral → Underperform
2024-11-18 개시 Oppenheimer Outperform
2024-08-16 개시 Cantor Fitzgerald Overweight
2024-06-28 개시 Truist Buy
2023-05-10 업그레이드 Wedbush Neutral → Outperform
2023-04-03 다운그레이드 Guggenheim Buy → Neutral
2023-01-27 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2023-01-05 다운그레이드 Cowen Outperform → Market Perform
2022-12-02 다운그레이드 BofA Securities Buy → Neutral
2022-10-31 다운그레이드 JP Morgan Neutral → Underweight
2022-10-31 다운그레이드 Wedbush Outperform → Neutral
2022-07-06 재개 Canaccord Genuity Buy
2022-06-24 개시 BMO Capital Markets Outperform
2022-02-03 재개 Guggenheim Buy
2021-11-19 재개 Morgan Stanley Equal-Weight
2021-11-16 다운그레이드 JP Morgan Overweight → Neutral
2021-05-07 업그레이드 BofA Securities Neutral → Buy
2021-04-23 재개 Cowen Outperform
2021-03-22 재개 JP Morgan Overweight
2021-01-15 다운그레이드 BofA Securities Buy → Neutral
2020-11-09 재확인 H.C. Wainwright Buy
2020-05-05 개시 Barclays Overweight
2020-05-01 개시 Janney Buy
2020-04-29 개시 Morgan Stanley Equal-Weight
2019-12-24 개시 JP Morgan Overweight
2019-11-20 개시 Guggenheim Buy
2019-09-04 개시 Wedbush Outperform
2019-04-01 개시 H.C. Wainwright Buy
2018-10-16 개시 BTIG Research Buy
2018-10-16 개시 BofA/Merrill Buy
모두보기

Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스

pulisher
Jul 20, 2025

Y mAbs Therapeutics Inc. Stock Analysis and ForecastRapidly growing investment returns - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Y mAbs Therapeutics Inc. stockUnprecedented profit potential - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Y mAbs Therapeutics Inc. stock priceExplosive earning power - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is Y mAbs Therapeutics Inc. a good long term investmentFree Technical Analysis Support - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 15, 2025

Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360

Jul 14, 2025
pulisher
Jul 11, 2025

Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener

Jul 11, 2025
pulisher
Jul 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Jul 04, 2025
pulisher
Jul 02, 2025

YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025
pulisher
Jun 25, 2025

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India

Jun 14, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025
pulisher
May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World

May 29, 2025
pulisher
May 28, 2025

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com

May 28, 2025

Y Mabs Therapeutics Inc (YMAB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):